Merck (MRK) Reports New Data from Phase 2b Clinical Trial Evaluating Efficacy and Safety of Islatravir in Combination With Doravirine

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to Merck (MRK) Reports New Data from Phase 2b Clinical Trial Evaluating Efficacy and Safety of Islatravir in Combination With Doravirine
Merck & Co. (NYSE: MRK) Delayed: 119.60 +4.12 (3.57%)
Previous Close $115.48    52 Week High $65.46 
Open $116.53    52 Week Low $47.97 
Day High $119.80    P/E 81.36 
Day Low $116.53    EPS $1.47 
Volume 11,893,949